"Herpesvirus 4, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
Descriptor ID |
D004854
|
MeSH Number(s) |
B04.280.210.400.500.450 B04.280.382.400.500.400 B04.613.204.500.500.400
|
Concept/Terms |
Herpesvirus 4, Human- Herpesvirus 4, Human
- Burkitt Lymphoma Virus
- Lymphoma Virus, Burkitt
- Burkitt's Lymphoma Virus
- Burkitts Lymphoma Virus
- E-B Virus
- E B Virus
- E-B Viruses
- Infectious Mononucleosis Virus
- Infectious Mononucleosis Viruses
- Mononucleosis Virus, Infectious
- Mononucleosis Viruses, Infectious
- Epstein-Barr Virus
- Epstein Barr Virus
- Herpesvirus 4 (gamma), Human
- HHV-4
- Human Herpesvirus 4
- Burkitt Herpesvirus
- Herpesvirus, Burkitt
- EBV
|
Below are MeSH descriptors whose meaning is more general than "Herpesvirus 4, Human".
Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 4, Human".
This graph shows the total number of publications written about "Herpesvirus 4, Human" by people in this website by year, and whether "Herpesvirus 4, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 1 | 2 |
2003 | 1 | 1 | 2 |
2004 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpesvirus 4, Human" by people in Profiles.
-
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
-
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas. Leuk Lymphoma. 2021 12; 62(14):3493-3500.
-
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. AIDS. 2020 05 01; 34(6):849-857.
-
Hepatitis C viremia is associated with cytomegalovirus IgG antibody levels in HIV-infected women. PLoS One. 2013; 8(4):e61973.
-
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. 2004 Oct 06; 96(19):1447-57.
-
Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
-
Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 01; 63(5):965-71.
-
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 2002 Oct 01; 100(7):2341-8.
-
Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res. 2002 Sep 01; 62(17):4876-8.
-
Possible role of Epstein-Barr virus infection in cutaneous T-cell lymphomas. J Invest Dermatol. 1990 Sep; 95(3):309-12.